IL218637A0 - Dosage regimen for administering an epcamxcd3 bispecific antibody - Google Patents

Dosage regimen for administering an epcamxcd3 bispecific antibody

Info

Publication number
IL218637A0
IL218637A0 IL218637A IL21863712A IL218637A0 IL 218637 A0 IL218637 A0 IL 218637A0 IL 218637 A IL218637 A IL 218637A IL 21863712 A IL21863712 A IL 21863712A IL 218637 A0 IL218637 A0 IL 218637A0
Authority
IL
Israel
Prior art keywords
administering
bispecific antibody
dosage regimen
epcamxcd3 bispecific
epcamxcd3
Prior art date
Application number
IL218637A
Other languages
English (en)
Original Assignee
Micromet Ag
Gerhard Zugmeier
Peter Kufer
Dominik Ruttinger
Sabine Kaubitzsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag, Gerhard Zugmeier, Peter Kufer, Dominik Ruttinger, Sabine Kaubitzsch filed Critical Micromet Ag
Publication of IL218637A0 publication Critical patent/IL218637A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL218637A 2009-09-18 2012-03-14 Dosage regimen for administering an epcamxcd3 bispecific antibody IL218637A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715 2009-09-18
US34414710P 2010-06-01 2010-06-01
EP10164596 2010-06-01
PCT/EP2010/063795 WO2011033105A1 (en) 2009-09-18 2010-09-20 Dosage regimen for administering an epcamxcd3 bispecific antibody

Publications (1)

Publication Number Publication Date
IL218637A0 true IL218637A0 (en) 2012-05-31

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218637A IL218637A0 (en) 2009-09-18 2012-03-14 Dosage regimen for administering an epcamxcd3 bispecific antibody

Country Status (15)

Country Link
US (1) US20120244161A1 (enExample)
EP (1) EP2477653A1 (enExample)
JP (1) JP2013505223A (enExample)
KR (1) KR20120083359A (enExample)
CN (1) CN102711825A (enExample)
AU (1) AU2010297258A1 (enExample)
BR (1) BR112012008345A2 (enExample)
CA (1) CA2774732A1 (enExample)
IL (1) IL218637A0 (enExample)
IN (1) IN2012DN03172A (enExample)
MX (1) MX2012003175A (enExample)
NZ (1) NZ598601A (enExample)
RU (1) RU2012115480A (enExample)
SG (2) SG179027A1 (enExample)
WO (1) WO2011033105A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR089114A1 (es) 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
CN105143270B (zh) * 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
JP6560682B2 (ja) * 2014-01-08 2019-08-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 小細胞肺癌に対する標的療法
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US10035856B2 (en) * 2015-11-19 2018-07-31 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
IL317013A (en) 2017-09-08 2025-01-01 Takeda Pharmaceuticals Co Binding proteins are activated under limited conditions
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
CN118201960B (zh) * 2021-11-19 2025-05-16 武汉友芝友生物制药股份有限公司 双特异性抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
SI1673398T1 (sl) 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
WO2006114115A1 (de) * 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs

Also Published As

Publication number Publication date
EP2477653A1 (en) 2012-07-25
JP2013505223A (ja) 2013-02-14
US20120244161A1 (en) 2012-09-27
RU2012115480A (ru) 2013-10-27
WO2011033105A1 (en) 2011-03-24
MX2012003175A (es) 2012-04-11
SG179027A1 (en) 2012-04-27
SG10201405434VA (en) 2014-10-30
BR112012008345A2 (pt) 2016-08-09
CA2774732A1 (en) 2011-03-24
CN102711825A (zh) 2012-10-03
IN2012DN03172A (enExample) 2015-09-25
KR20120083359A (ko) 2012-07-25
NZ598601A (en) 2014-05-30
AU2010297258A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IL218637A0 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
IL219301A (en) A method of determining dosage for the administration of a biphasic 3xcd19cd antibody
HRP20181254T1 (hr) Režim doziranja za multiplu sklerozu
PL2794626T3 (pl) Związki antagonistyczne E-selektyny
IL225953A0 (en) An antidote–her@@pan
IL229254A0 (en) Therapeutic antibodies
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
KR102493433B9 (ko) 항-α4β7 항체에 대한 제형
PL2636736T3 (pl) Nowe przeciwciało anty-dr5
ZA201404270B (en) Dosage regimen of an s1p receptor modulator
ZA201206529B (en) Antigen priteins specific for serum amyloid p component
ZA201402283B (en) Dosage regimen for an s1p receptor modulator or agonist
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
GB201108529D0 (en) Contrast agents for biophotonic imaging
HK1170940A (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
ZA201308992B (en) Therapeutic antibodies